


DW-1350

| | |
|--------------------|---|
| Cat. No.: | HY-100173 |
| CAS No.: | 491577-61-8 |
| Molecular Formula: | C ₂₅ H ₃₁ N ₃ O ₃ S |
| Molecular Weight: | 453.6 |
| Target: | Leukotriene Receptor |
| Pathway: | GPCR/G Protein |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | |
|---------------------------|---|
| Description | DW-1350 is a LTB ₄ receptor antagonist. |
| IC ₅₀ & Target | LTB ₄ |
| In Vitro | DW-1350 is a LTB ₄ receptor antagonist. DW-1350 shows inhibitory effects against osteoclast in terms of differentiation, formation, fusion and bone absorption ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

[1]. Kang JH, et al. 5-Lipoxygenase inhibitors suppress RANKL-induced osteoclast formation via NFATc1 expression. *Bioorg Med Chem*. 2015 Nov 1;23(21):7069-78.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA